Kurzfassung

A randomized, double-blind, placebo controlled, phase III trial to evaluate the protective efficacy and safety of a therapeutic vaccine, ASP0113, in cytomegalovirus(CMV)-seropositive recipients undergoing allogeneic hematopoietic cell transplant (HCT)